Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress

Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemigatinib, whose approval has marked a new era in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadaleta-Caldarola, Gennaro, Rizzo, Alessandro, Dadduzio, Vincenzo, Lombardi, Lucia, Gadaleta-Caldarola, Arianna, Infusino, Stefania, Cusmai, Antonio, Citrigno, Claudia, Palmiotti, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600707/
https://www.ncbi.nlm.nih.gov/pubmed/36290903
http://dx.doi.org/10.3390/curroncol29100626
_version_ 1784816910030864384
author Gadaleta-Caldarola, Gennaro
Rizzo, Alessandro
Dadduzio, Vincenzo
Lombardi, Lucia
Gadaleta-Caldarola, Arianna
Infusino, Stefania
Cusmai, Antonio
Citrigno, Claudia
Palmiotti, Gennaro
author_facet Gadaleta-Caldarola, Gennaro
Rizzo, Alessandro
Dadduzio, Vincenzo
Lombardi, Lucia
Gadaleta-Caldarola, Arianna
Infusino, Stefania
Cusmai, Antonio
Citrigno, Claudia
Palmiotti, Gennaro
author_sort Gadaleta-Caldarola, Gennaro
collection PubMed
description Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemigatinib, whose approval has marked a new era in this hepatobiliary malignancy. However, a number of questions remain unanswered, including the development of secondary resistance and the role of combination therapies, including FGFR inhibitors. Herein, we specifically focus on the current challenges and future research directions of pemigatinib use in CCA patients.
format Online
Article
Text
id pubmed-9600707
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96007072022-10-27 Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress Gadaleta-Caldarola, Gennaro Rizzo, Alessandro Dadduzio, Vincenzo Lombardi, Lucia Gadaleta-Caldarola, Arianna Infusino, Stefania Cusmai, Antonio Citrigno, Claudia Palmiotti, Gennaro Curr Oncol Perspective Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemigatinib, whose approval has marked a new era in this hepatobiliary malignancy. However, a number of questions remain unanswered, including the development of secondary resistance and the role of combination therapies, including FGFR inhibitors. Herein, we specifically focus on the current challenges and future research directions of pemigatinib use in CCA patients. MDPI 2022-10-19 /pmc/articles/PMC9600707/ /pubmed/36290903 http://dx.doi.org/10.3390/curroncol29100626 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Gadaleta-Caldarola, Gennaro
Rizzo, Alessandro
Dadduzio, Vincenzo
Lombardi, Lucia
Gadaleta-Caldarola, Arianna
Infusino, Stefania
Cusmai, Antonio
Citrigno, Claudia
Palmiotti, Gennaro
Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
title Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
title_full Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
title_fullStr Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
title_full_unstemmed Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
title_short Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
title_sort pemigatinib in intrahepatic cholangiocarcinoma: a work in progress
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600707/
https://www.ncbi.nlm.nih.gov/pubmed/36290903
http://dx.doi.org/10.3390/curroncol29100626
work_keys_str_mv AT gadaletacaldarolagennaro pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT rizzoalessandro pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT dadduziovincenzo pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT lombardilucia pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT gadaletacaldarolaarianna pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT infusinostefania pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT cusmaiantonio pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT citrignoclaudia pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress
AT palmiottigennaro pemigatinibinintrahepaticcholangiocarcinomaaworkinprogress

Ejemplares similares